10x Genomics (TXG) CFO granted 106,579 RSUs in new equity award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Taich Adam reported acquisition or exercise transactions in this Form 4 filing.

10x Genomics Chief Financial Officer Adam Taich received an equity award of 106,579 shares of Class A Common Stock in the form of restricted stock units (RSUs). The award was granted at no cash cost per share and increases his directly held beneficial ownership to 394,996 shares.

The RSUs vest over time, with 1/12 of the units vesting on each quarterly anniversary starting from February 21, 2026, as long as he continues as a service provider through each vesting date. This structure is designed to align his compensation with the company’s long-term performance and retention.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Taich Adam

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	106,579	$0.00	--

Holdings After Transaction: Class A Common Stock — 394,996 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/02/2026 - 04:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taich Adam

(Last)

(First)

(Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON

94588

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/26/2026		A		106,579⁽¹⁾	A	$0	394,996	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/12th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

	/s/ Randy Wu, as Attorney-in-Fact for Adam Taich	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did 10x Genomics (TXG) report for CFO Adam Taich?

10x Genomics reported that CFO Adam Taich received a grant of 106,579 restricted stock units of Class A Common Stock. These equity awards were recorded as an acquisition at no cash cost per share and increase his directly held beneficial ownership to 394,996 shares.

How many shares did the 10x Genomics (TXG) CFO acquire in this Form 4 filing?

The CFO acquired 106,579 shares in the form of restricted stock units of Class A Common Stock. These RSUs represent a contingent right to receive one share each upon vesting, adding to his total directly owned 394,996 shares after the grant recorded in this filing.

What are the vesting terms of the RSUs granted to 10x Genomics (TXG) CFO Adam Taich?

The RSUs vest in 12 equal installments, with 1/12 vesting on each quarterly anniversary starting from February 21, 2026. Vesting is contingent on Adam Taich continuing as a service provider to 10x Genomics through each applicable vesting date specified in the award terms.

Did CFO Adam Taich buy 10x Genomics (TXG) shares on the open market?

No, the filing shows a grant of restricted stock units, not an open-market purchase. The transaction code is an acquisition through a grant or award at a stated price of zero, reflecting equity-based compensation rather than a market transaction for cash consideration.

How many 10x Genomics (TXG) shares does the CFO own after this RSU grant?

After the reported grant, CFO Adam Taich holds 394,996 shares of Class A Common Stock directly. This total includes the newly awarded 106,579 restricted stock units, which each convert into one share of Class A Common Stock as they vest over time.

What does each restricted stock unit (RSU) in the 10x Genomics (TXG) award represent?

Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. The units do not settle immediately but convert into shares over the vesting schedule, conditioned on the CFO’s continued service to 10x Genomics through each vesting date.